DK1594434T3 - Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus - Google Patents

Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus

Info

Publication number
DK1594434T3
DK1594434T3 DK04702215.7T DK04702215T DK1594434T3 DK 1594434 T3 DK1594434 T3 DK 1594434T3 DK 04702215 T DK04702215 T DK 04702215T DK 1594434 T3 DK1594434 T3 DK 1594434T3
Authority
DK
Denmark
Prior art keywords
peptide
treatment
lupus erythematosus
systemic lupus
parenteral formulations
Prior art date
Application number
DK04702215.7T
Other languages
English (en)
Inventor
Sharon Cohen-Vered
Esmira Naftali
Vera Weinstein
Adrian Gilbert
Ety Klinger
Original Assignee
Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science filed Critical Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science
Application granted granted Critical
Publication of DK1594434T3 publication Critical patent/DK1594434T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK04702215.7T 2003-01-14 2004-01-14 Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus DK1594434T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43991803P 2003-01-14 2003-01-14
PCT/US2004/000948 WO2004064787A2 (en) 2003-01-14 2004-01-14 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
DK1594434T3 true DK1594434T3 (da) 2017-01-02

Family

ID=32771757

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04702215.7T DK1594434T3 (da) 2003-01-14 2004-01-14 Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus

Country Status (21)

Country Link
US (3) US20050008634A1 (da)
EP (1) EP1594434B1 (da)
JP (2) JP4817068B2 (da)
KR (1) KR20050100617A (da)
CN (1) CN1774259B (da)
AU (1) AU2004206842A1 (da)
BR (1) BRPI0406745A (da)
CA (1) CA2513320C (da)
CO (1) CO5640143A2 (da)
CR (1) CR7938A (da)
DK (1) DK1594434T3 (da)
EA (1) EA009123B1 (da)
EC (1) ECSP055961A (da)
ES (1) ES2606464T3 (da)
IL (1) IL169574A (da)
IS (1) IS7972A (da)
MX (1) MXPA05007549A (da)
NO (1) NO20053773L (da)
NZ (1) NZ541658A (da)
WO (1) WO2004064787A2 (da)
ZA (1) ZA200506206B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
KR20050100617A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형
JP2006516034A (ja) * 2003-01-14 2006-06-15 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスを治療するためのペプチドの非経口製剤
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
MX2011005051A (es) * 2008-11-17 2011-06-01 Genentech Inc Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas.
WO2013123254A1 (en) 2012-02-15 2013-08-22 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
BR112015000497A2 (pt) * 2012-07-12 2017-06-27 Sanofi Sa composição anti-tumoral compreendendo o composto 1-(6-{[6-(4-fluorofenil)[1,2,4]triazolo[4,3-b]piridazin-3-il]sulfanil}-1,3-benzotiazol-2-il)-3-(2-morfolin-4-iletil)ureia
KR102112119B1 (ko) 2012-10-22 2020-05-19 사이덱스 파마슈티칼스, 인크. 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
WO2015013669A1 (en) 2013-07-26 2015-01-29 The Regents Of The University Of California Mps peptides and use thereof
US10314889B2 (en) * 2013-12-20 2019-06-11 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
PT3183295T (pt) 2014-08-22 2023-11-03 Cydex Pharmaceuticals Inc Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas
CN115400220A (zh) 2015-12-30 2022-11-29 豪夫迈·罗氏有限公司 减少聚山梨酯降解的制剂
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
CA3047706A1 (en) 2017-01-05 2018-07-12 Yeda Research And Development Co. Ltd. Peptides for treating sjogren's syndrome
WO2018186343A1 (ja) * 2017-04-04 2018-10-11 日東電工株式会社 凍結乾燥体の製造方法及びその製造装置
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
WO2019108285A1 (en) * 2017-11-30 2019-06-06 Cytogel Pharma, Llc Novel analgesic pharmaceutical formulations and uses thereof
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
IL120503A0 (en) * 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US20020054872A1 (en) * 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
JP2006516034A (ja) * 2003-01-14 2006-06-15 テバ ファーマシューティカル インダストリーズ リミティド 全身性エリテマトーデスを治療するためのペプチドの非経口製剤
KR20050100617A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형
US7018891B2 (en) * 2003-12-16 2006-03-28 International Business Machines Corporation Ultra-thin Si channel CMOS with improved series resistance

Also Published As

Publication number Publication date
EP1594434B1 (en) 2016-09-07
IS7972A (is) 2006-07-15
EA200501131A1 (ru) 2006-04-28
CA2513320A1 (en) 2004-08-05
ECSP055961A (es) 2006-04-19
US20050008634A1 (en) 2005-01-13
JP4817068B2 (ja) 2011-11-16
MXPA05007549A (es) 2006-05-19
CA2513320C (en) 2018-03-27
CR7938A (es) 2006-05-31
NZ541658A (en) 2008-04-30
EP1594434A4 (en) 2008-09-10
NO20053773D0 (no) 2005-08-08
NO20053773L (no) 2005-10-12
WO2004064787A3 (en) 2005-12-15
JP2006517540A (ja) 2006-07-27
KR20050100617A (ko) 2005-10-19
BRPI0406745A (pt) 2005-12-20
EA009123B1 (ru) 2007-10-26
US20130023485A1 (en) 2013-01-24
EP1594434A2 (en) 2005-11-16
ZA200506206B (en) 2006-12-27
ES2606464T3 (es) 2017-03-24
IL169574A0 (en) 2007-07-04
IL169574A (en) 2015-08-31
CN1774259B (zh) 2011-12-28
AU2004206842A1 (en) 2004-08-05
CO5640143A2 (es) 2006-05-31
CN1774259A (zh) 2006-05-17
US20090169559A1 (en) 2009-07-02
JP2011173888A (ja) 2011-09-08
WO2004064787A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
DK1594434T3 (da) Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
DK1575416T3 (da) Fremgangsmåder til diagnosticering af præeklampsi
DK1663287T3 (da) Anvendelse af modificerede cyclosporiner til behandling af HCV-sygdomme
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
DE602004030390D1 (de) Digitalkamera
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
EP1653935A4 (en) INFLAMMATORY FORMULATIONS
DE502004001561D1 (de) Kamera
DK1803718T3 (da) 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter
MX266708B (es) Formulaciones de microparticulas de pantoprazol.
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DK1744866T3 (da) Fremgangsmåde til at vælge formuleringer til behandling af elektriske kabler
NO20053761D0 (no) Parenterale peptidformuleringer for behandling av systemisk lupus erythematosus.
IS8309A (is) Lyfjablöndur
EP1692279A4 (en) VIRUS PREPARATIONS CONTAINING A CONSERVATIVE
EP1690716A4 (en) OPENING ROOF DEVICE
DK1727801T3 (da) Til behandling af smerter anvendelige piperaziner
DE602004001644D1 (de) Festkörperbildaufnahmevorrichtung
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
DK1541137T3 (da) Transdermalt delivery system af gestoden
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme
DE602004012747D1 (de) Digitalkamerasystem
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
DE602004006752D1 (de) Autofokussystem
DK1654280T3 (da) Fremstilling af somatostatinpeptider